After adjusting for the effects of age and gender, subjects with apM1 +45 TT genotype were not at significantly higher risk of MetS compared to those with apM1 +45 TG/GG genotypes in the dominant model (OR = 1.34, 95% CI 0.85-2.11). This evidence concerns the gene ADIPOQ and metabolic syndrome.